Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOL-303242-X ophthalmic suspension dose-ranging study after cataract surgery
2009-011913-26Phase 2Terminated
- Sponsor
- Dr Gerhard Mann
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Postoperative ocular inflammation comparing BOL-303242-X ophthalmic suspension with Vehicle control (2 arms). Primary endpoint: Complete resolution of anterior chamber cells at Visit 5. Started Jan 2010; status: terminated.
02
Drugs
mapracorat
03
Conditions
Postoperative ocular inflammation
Beyond the preview
Go deeper on 2009-011913-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011913-26.